华兰生物重组Exendin-4-Fc融合蛋白注射液临床试验获批

Core Viewpoint - The announcement indicates that Hualan Biological has received approval from the National Medical Products Administration for clinical trials of its recombinant Exendin-4-Fc fusion protein injection (HL08) for use in overweight or obese adults, expanding its application beyond type 2 diabetes management [1] Group 1 - Hualan Biological's HL08 has been approved for clinical trials to improve weight control in obese patients, in addition to its original indication for blood sugar control in type 2 diabetes patients [1] - The approval allows the company to officially conduct clinical research to further verify the safety and efficacy of HL08, laying the groundwork for future registration and market launch [1] - This new indication enhances the company's biopharmaceutical product pipeline and optimizes its product structure [1]